Compare AbbVie Inc (ABBV) vs BlackBerry Limited (BB) Price & Performance

AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.

The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.

BlackBerry (BB) trades at $11.10, down 3.56% on the day but remains in a strong uptrend, having more than tripled year-to-date. The stock is technically bullish with recent earnings beats and improved guidance fueling optimism. Revenue growth is returning, with Q1 2026 results showing a profit turnaround, though valuation multiples remain elevated. Positive sentiment is driven by QNX software growth and the launch of leveraged ETFs tied to the stock.

Outlook is cautiously optimistic as execution on QNX and cybersecurity growth must justify high valuations. Key risks include competitive pressures and the need to sustain profitability. Analysts are mostly neutral with a consensus price target of $10.50, suggesting limited near-term upside from current levels amid rich pricing.